Markets

Singulex withdraws $70 million IPO

Singulex, which provides diagnostic testing for cardiovascular disease in a non-acute setting, withdrew its plans for an initial public offering on Friday citing poor market conditions. Singulex had postponed its planned $70 million offering in November. The Alameda, CA-based company was founded in 1997 and booked $38 million in sales for the 12 months ended 6/30/2012. UBS Investment Bank and Piper Jaffray were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More